Recombinant Fusion Proteins
"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
| Descriptor ID |
D011993
|
| MeSH Number(s) |
D12.776.828.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".
This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 11 | 29 | 40 |
| 1995 | 13 | 30 | 43 |
| 1996 | 8 | 33 | 41 |
| 1997 | 2 | 52 | 54 |
| 1998 | 4 | 40 | 44 |
| 1999 | 2 | 36 | 38 |
| 2000 | 5 | 58 | 63 |
| 2001 | 6 | 44 | 50 |
| 2002 | 16 | 55 | 71 |
| 2003 | 10 | 48 | 58 |
| 2004 | 9 | 56 | 65 |
| 2005 | 6 | 45 | 51 |
| 2006 | 7 | 39 | 46 |
| 2007 | 5 | 34 | 39 |
| 2008 | 6 | 24 | 30 |
| 2009 | 8 | 51 | 59 |
| 2010 | 10 | 24 | 34 |
| 2011 | 19 | 29 | 48 |
| 2012 | 8 | 17 | 25 |
| 2013 | 6 | 17 | 23 |
| 2014 | 14 | 18 | 32 |
| 2015 | 9 | 9 | 18 |
| 2016 | 7 | 14 | 21 |
| 2017 | 12 | 16 | 28 |
| 2018 | 7 | 7 | 14 |
| 2019 | 10 | 6 | 16 |
| 2020 | 16 | 5 | 21 |
| 2021 | 5 | 10 | 15 |
| 2022 | 2 | 15 | 17 |
| 2023 | 2 | 10 | 12 |
| 2024 | 7 | 7 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.
-
Is luspatercept the new standard of care in transfusion-dependent low-risk myelodysplastic syndromes? Clin Adv Hematol Oncol. 2024 Oct; 22(8):367-369.
-
Safety and efficacy of luspatercept for the treatment of anemia in?patients with myelofibrosis. Blood Adv. 2024 09 10; 8(17):4511-4522.
-
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 08 01; 109(8):2660-2664.
-
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
-
Biochemical Characterization and Application of Zearalenone Lactone Hydrolase Fused with a Multifunctional Short Peptide. J Agric Food Chem. 2024 Aug 14; 72(32):18146-18154.
-
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024 Sep; 11(9):e646-e658.
-
A method for rapid and reliable quantification of VEGF-cell binding activity. Biochem Biophys Res Commun. 2024 10 01; 727:150321.
-
Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature. Cancer. 2024 Jul 01; 130(13):2260-2271.
-
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leuk Res. 2024 04; 139:107479.
-
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024 Mar 23; 403(10432):1153-1163.